Inquiry Basket
Loading ......
Vitamin D is best known for its role in calcium balance and bone health, but its biological effects extend well beyond the skeletal system. Increasing evidence indicates that vitamin D participates in immune regulation, influencing T-cell differentiation, antigen-presenting cell activity, inflammatory signaling, and immune tolerance. Because 25-hydroxyvitamin D [25(OH)D] is the major circulating form of vitamin D and has a relatively long half-life, serum 25(OH)D is widely used as the primary laboratory marker of vitamin D status. A growing body of research has linked low 25(OH)D concentrations with autoimmune conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS). However, the relationship is biologically complex. Vitamin D deficiency may contribute to immune dysregulation in some individuals, while inflammation, reduced sunlight exposure, limited mobility, medication use, or other disease-related factors may also lower circulating 25(OH)D. Understanding this two-way relationship is important when interpreting vitamin D testing and considering its potential role in autoimmune disease management.
The immune effects of vitamin D depend largely on the vitamin D receptor (VDR), a nuclear receptor expressed by many immune cells, including monocytes, macrophages, dendritic cells, and activated T cells. After vitamin D enters the circulation, it is converted in the liver to 25(OH)D, which serves as the principal circulating reservoir. Immune cells can then locally convert 25(OH)D to the biologically active metabolite 1,25-dihydroxyvitamin D [1,25(OH)2D] through the enzyme 1α-hydroxylase. This local vitamin D system allows immune cells to respond to the availability of 25(OH)D within their microenvironment. When circulating 25(OH)D is low, there may be less substrate available for local production of active vitamin D metabolites. Consequently, vitamin D-dependent regulatory signals may become less effective precisely where immune activation is occurring. This does not mean that a low 25(OH)D result automatically causes autoimmune disease. Rather, it provides a plausible biological link between inadequate vitamin D availability and impaired regulation of inflammatory immune responses.
One of the most extensively studied mechanisms involves the balance between inflammatory and regulatory T-cell populations. Active vitamin D can influence CD4+ T-cell differentiation, generally suppressing excessive Th1 and Th17 responses while favoring regulatory pathways, including regulatory T cells (Tregs). Th1 and Th17 cells are important for effective host defense, but excessive or poorly controlled activity can contribute to chronic inflammation and autoimmune tissue damage. Tregs, in contrast, help maintain immune tolerance by limiting inappropriate immune responses against the body's own tissues. A disruption in the balance between these populations may therefore create an environment more favorable to autoimmunity. Observational research in patients with newly diagnosed childhood SLE has reported associations between serum 25(OH)D concentrations and T-cell profiles. Higher 25(OH)D levels have been associated with greater proportions of Tregs and lower proportions of Th17 cells, supporting the concept that vitamin D status may be connected to the maintenance of immune tolerance.
Vitamin D also interacts with intracellular signaling pathways involved in inflammation, cell differentiation, proliferation, and survival. Through VDR-dependent transcriptional regulation, vitamin D signaling can influence pathways involving NF-κB, MAP kinases, TGF-β, Wnt/β-catenin, and growth-factor signaling. NF-κB is particularly important because it regulates the expression of numerous inflammatory mediators. Excessive activation of this pathway can promote sustained production of inflammatory cytokines and contribute to tissue injury. Vitamin D signaling may help restrain some of these inflammatory processes, whereas inadequate vitamin D availability may reduce this regulatory influence. Vitamin D can also affect immune-cell differentiation and programmed cell death. Together, these effects suggest that adequate vitamin D signaling may help prevent prolonged immune activation rather than simply suppressing the immune system. This distinction is important: healthy immune regulation requires a balance between effective defense against pathogens and appropriate control of inflammation.
Autoimmune disease is influenced not only by genes themselves but also by how genes are expressed. Epigenetic mechanisms, including DNA methylation, histone modification, and non-coding RNA regulation, can alter gene activity without changing the underlying DNA sequence. Vitamin D has been investigated as a potential nutritional regulator of these epigenetic processes. VDR signaling can interact with transcriptional machinery and regulatory regions throughout the genome, potentially influencing the expression of genes involved in inflammation and immune tolerance. This area remains an active field of research. It would be premature to describe vitamin D deficiency as a direct epigenetic cause of autoimmune disease, but the evidence supports a broader model in which nutritional status, environmental exposures, genetic background, and immune regulation interact over time.
Not everyone with low 25(OH)D develops autoimmune disease, and genetic susceptibility may partly explain this variation. Vitamin D-responsive elements, or VDREs, are present in regulatory regions associated with numerous genes. Genetic variants affecting vitamin D transport, metabolism, VDR signaling, or downstream transcription may therefore influence how an individual responds to available vitamin D. Variants in or around the VDR gene and other vitamin D pathway genes have been investigated in relation to autoimmune conditions. Some studies suggest that particular genetic backgrounds may alter vitamin D status or modify disease susceptibility. However, associations between individual genetic variants and autoimmune disease can vary among populations, and genetic findings should not be interpreted as deterministic predictors. The emerging picture is therefore more nuanced: vitamin D status may interact with inherited susceptibility rather than acting as an isolated cause of autoimmunity.
The relationship between vitamin D status and SLE has attracted considerable attention. Patients with SLE frequently have low 25(OH)D concentrations, potentially because of reduced sun exposure, photosensitivity precautions, disease activity, kidney involvement, corticosteroid use, or other factors. Studies in patients with newly diagnosed childhood SLE have found lower serum 25(OH)D concentrations compared with healthy controls. Lower vitamin D status has also been associated in some cohorts with higher disease activity and greater organ damage. An especially important observation concerns lupus nephritis, a serious renal manifestation of SLE. Some studies have reported a higher frequency of lupus nephritis among patients with vitamin D deficiency or insufficiency. These findings are clinically interesting because they raise the possibility that 25(OH)D could serve as one component of a broader assessment of disease status and organ involvement. However, 25(OH)D should not be used alone to predict lupus nephritis or determine treatment decisions.
Vitamin D signaling may also influence immune pathways involved in rheumatoid arthritis. By affecting Th1, Th17, and Treg activity as well as inflammatory signaling, vitamin D could potentially modify the immune environment associated with chronic synovial inflammation. Clinical research has produced mixed results regarding vitamin D supplementation and RA outcomes. Some studies support associations between lower vitamin D status and disease activity, whereas intervention studies have not consistently demonstrated that supplementation produces substantial improvements in established autoimmune disease. This distinction highlights why correcting deficiency and treating autoimmune disease should be viewed as related but separate clinical objectives.
Multiple sclerosis provides another important example of the relationship between vitamin D and autoimmunity. Epidemiological research has repeatedly associated lower vitamin D status with a greater risk of MS, particularly in populations with limited ultraviolet-B exposure. Genetic epidemiology, including Mendelian randomization studies, has provided additional evidence supporting a potential causal relationship between genetically predicted lower 25(OH)D concentrations and MS risk. Nevertheless, questions remain regarding the optimal vitamin D level, the most effective timing of supplementation, and whether supplementation can prevent disease onset or meaningfully alter established disease.
This is one of the most important questions when interpreting the available evidence. A low 25(OH)D concentration can theoretically contribute to immune dysregulation. At the same time, autoimmune disease itself can lower vitamin D status. Patients with chronic inflammatory disease may spend less time outdoors, experience reduced physical activity, change their diet, develop organ dysfunction, or take medications that affect vitamin D metabolism. This creates a potential bidirectional relationship. In other words, low vitamin D may increase susceptibility in some circumstances, while autoimmune inflammation may simultaneously make vitamin D deficiency more likely. Randomized clinical trials and Mendelian randomization studies can help address this issue, but they do not completely resolve it. Some intervention research suggests potential benefits of vitamin D supplementation for autoimmune disease prevention, while evidence for treating established autoimmune disease remains less consistent. Therefore, vitamin D deficiency should currently be viewed as a potentially modifiable factor within a much larger network of genetic, environmental, metabolic, and immunological influences.
Because serum 25(OH)D reflects the body's major circulating vitamin D reservoir, it is the preferred laboratory marker for assessing vitamin D status. Testing can be particularly relevant when a person has established risk factors for deficiency, limited sunlight exposure, malabsorption concerns, certain chronic diseases, or other clinical reasons for assessment. Importantly, the interpretation of a 25(OH)D result should consider the clinical context. A single laboratory value does not diagnose an autoimmune disease, establish causality, or reliably predict disease activity on its own. Autoimmune conditions require appropriate clinical assessment and disease-specific laboratory or imaging investigations when indicated. For individuals with confirmed vitamin D deficiency, correction of inadequate vitamin D status may support overall health and normal physiological function. Whether supplementation prevents or treats a particular autoimmune disease is a separate question that requires disease-specific evidence.
Current evidence supports a biologically plausible connection between vitamin D status and immune regulation, but it does not justify treating vitamin D as a universal therapy for autoimmune disease. Maintaining adequate vitamin D status is reasonable for bone health and general physiological needs, particularly in people at increased risk of deficiency. For patients with autoimmune disease, vitamin D assessment may provide useful information when deficiency is suspected or when clinical circumstances warrant testing. If supplementation is needed, the appropriate dose and monitoring strategy should be individualized according to baseline 25(OH)D concentration, age, dietary intake, kidney and other health considerations, and the patient's overall clinical situation. Most importantly, vitamin D supplementation should complement—not replace—evidence-based treatment for autoimmune disease. Disease-modifying therapies, anti-inflammatory treatments, monitoring, and management of specific organ complications remain central to care.
The relationship between 25(OH)D deficiency and autoimmune disease is best understood as part of a complex biological network rather than a simple cause-and-effect pathway. Vitamin D can influence T-cell differentiation, regulatory immune pathways, inflammatory signaling, epigenetic regulation, and interactions between genetic susceptibility and environmental factors. When 25(OH)D availability is inadequate, these regulatory mechanisms may become less effective, potentially contributing to an immune environment in which inflammatory responses are harder to control. At the same time, autoimmune disease itself can contribute to low vitamin D status, making the direction of causality difficult to establish in observational studies. For this reason, 25(OH)D testing provides valuable information about vitamin D status, but the result should always be interpreted alongside clinical findings and other laboratory data. As research continues to clarify the relationship between vitamin D and autoimmunity, maintaining adequate vitamin D status remains a practical component of overall health while its disease-specific therapeutic potential continues to be evaluated.
25-OH vitamin D, or 25-hydroxyvitamin D [25(OH)D], is the main circulating form of vitamin D and the standard blood marker used to assess vitamin D status. It also provides substrate for local production of active vitamin D metabolites in immune cells. Low 25(OH)D levels have been associated with altered immune regulation and several autoimmune diseases, although deficiency alone does not establish that vitamin D causes autoimmunity.
Vitamin D signaling through the vitamin D receptor (VDR) can influence T-cell differentiation, regulatory T-cell activity, inflammatory signaling, and antigen-presenting cell function. Inadequate vitamin D availability may contribute to an imbalance between inflammatory Th1/Th17 responses and immune-tolerant Treg responses, potentially promoting persistent inflammation.
Low 25(OH)D levels have been reported in people with systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. In SLE, lower vitamin D status has also been associated with greater disease activity and lupus nephritis in some studies. However, the strength and clinical significance of these associations vary among diseases, and vitamin D deficiency should not be considered a standalone cause.
Correcting vitamin D deficiency is important for maintaining normal physiological health, but vitamin D supplementation should not be considered a replacement for established autoimmune disease treatments. Evidence for preventing autoimmune disease or improving established disease through supplementation remains mixed and appears to depend on the specific disease, baseline vitamin D status, dose, and patient characteristics.
Testing may be appropriate when vitamin D deficiency is suspected or when a person has recognized risk factors for deficiency. A 25(OH)D result should be interpreted together with medical history, symptoms, disease-specific tests, and other clinical information. Supplementation should ideally be guided by an appropriate healthcare professional, particularly when high-dose treatment is being considered.
References
| Target | Cat. No. | Product Name | Host | Application | |
| 25-OH Vitamin D | DMABA-JX119 | Rabbit Anti-25 OH Vitamin D monoclonal antibody, clone S594L4 | Rabbit | ELISA, LFIA, CLIA | Inquiry |
| DMABA-JX120 | Rabbit Anti-25 OH Vitamin D monoclonal antibody, clone S595K5 | Rabbit | ELISA, LFIA, CLIA | Inquiry | |
| DMAB-JXL2399 | Goat Anti-25-OH VD2/VD3 Monoclonal Antibody, clone 5C3 | CHO | ELISA, CLIA, LFIA | Inquiry | |
| DMAB2913 | Mouse Anti-25 OH Vitamin D3 monoclonal antibody, clone L35235N | Mouse | ELISA | Inquiry | |
| DMAB2914 | Mouse Anti-25 OH Vitamin D3 Monoclonal antibody, clone C2531M | Mouse | ELISA | Inquiry | |
| CABT-L1343W | Humanized Anti-Human 25-OH-VD Monoclonal antibody, clone 214I2T | Humanized | LFIA, CLIA | Inquiry | |
| CABT-L1344W | Humanized Anti-Human 25-OH-VD Monoclonal antibody, clone 214I5 | Humanized | PETIA | Inquiry |
| Target | Cat. No. | Product Name | Conjugate | Application | |
| 25-OH Vitamin D | DAG-WT2678 | 25-hydroxyvitamin D control | Unconjugated | Calibration, Control | Inquiry |
| DAG-WT2679 | 25-hydroxyvitamin D2 control | Unconjugated | Calibration, Control | Inquiry | |
| DAG-WT2680 | 25-hydroxyvitamin D3 control | Unconjugated | Calibration, Control | Inquiry | |
| DAG03219 | 25-OH Vitamin D3 [BSA] | BSA | ELISA, LFIA | Inquiry | |
| DAGA-126H | 25-OH Vitamin D [HRP] | HRP | ELISA | Inquiry | |
| DAGA-126K | 25-OH Vitamin D [KLH] | KLH | Immunogen | Inquiry | |
| DAG-WT6032B | 25-OH Vitamin D2 [BSA] | BSA | ELISA, LFIA | Inquiry |
| Target | Cat. No. | Product Name | Species Reactivity | Application | Detection Sample | |
| 25-OH Vitamin D | DEIA4458 | 25-OH Vitamin D ELISA Kit | Human | Quantitative | Serum, Plasma | Inquiry |
| DEIA1733 | 25 (OH) Vitamin D ELISA Kit | Human | Quantitative | plasma, serum | Inquiry | |
| DEIA002J | 25-OH Vitamin D direct (1-point calibration) ELISA Kit | Human | Quantitative | serum | Inquiry | |
| DEIA003J | 25-OH Vitamin D direct day ELISA Kit | Human | Quantitative | serum, fresh plasma | Inquiry | |
| DEIA004J | 25-OH Vitamin D direct ELISA Kit | Human | Quantitative | serum, fresh plasma | Inquiry | |
| DEIA005J | 25-OH Vitamin D Xpress ELISA Kit | Human | Quantitative | serum, fresh EDTA plasma | Inquiry | |
| DEIA006J | 25-OH Vitamin D ELISA Kit | Human | Quantitative | serum, plasma | Inquiry | |
| DEIA2219 | 25-OH Vitamin D (total) ELISA Kit 0 2 | Human | Quantitative | Serum | Inquiry | |
| DEIA-BJ574-1 | Human 25 (OH) D3 ELISA kit | Human | Quantitative | Serum, plasma and other biological fluids. | Inquiry | |
| DEIA-BJ2145 | Rat 25 Hydroxy Vitamin D3 ELISA Kit | Rat | Quantitative | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate | Inquiry | |
| DEIA-NS2651 | 25OH-D (Total 25-OH Vitamin D) ELISA Kit | Universal | Quantitative | Serum, plasma, cellculture supernatant and other biological samples. | Inquiry | |
| DEIA-BJ648 | Human 25 Hydroxy Vitamin D ELISA kit | Human | Quantitative | biological fluids. | Inquiry |
Loading ......
